North America Liver Disease Treatment Market to Hit $8.31 Billion by 2027: AMR

Increase in consumption of alcoholic beverages and use of illegal drugs and increased government and private awareness programs have boosted the growth of the North America liver disease treatment market. The market across Mexico is expected to manifest the highest CAGR of 6.8% during the forecast period. Majority of the immunization programs are halted and the demand for immunosuppressants has decreased due to reduction in liver transplant during lockdown.


Portland, Oct. 26, 2020 (GLOBE NEWSWIRE) -- As per the report published by Allied Market Research, the North America Liver Disease Treatment Market accounted for $6.97 billion in 2019, and is projected to reach $8.31 billion by 2027, growing at a CAGR of 5.2% from 2020 to 2027.

Increase in consumption of alcoholic beverages and use of illegal drugs, surge in the geriatric population, surge in prevalence of liver diseases, and increased government and private awareness programs have boosted the growth of the North America liver disease treatment market. However, strict regulatory approvals regarding liver disease treatment drugs and vaccines and resistance to antiviral drugs used in treatment of hepatitis B and hepatitis C hamper the market. On the contrary, presence of strong pipeline products is expected to open new opportunities for the market players.

Download Detailed COVID-19 Impact Sample Report at: https://www.alliedmarketresearch.com/request-for-customization/7546?reqfor=covid

Covid-19 scenario:

The lockdown imposed by governments across the globe has led to disruption in the supply-demand of medicines and lack of healthcare professionals for liver disease treatment.

Majority of the immunization programs are halted and the demand for immunosuppressants has decreased due to reduction in liver transplant during the lockdown.

The North America liver disease treatment market is divided on the basis of treatment type, disease type, and country. Based on treatment type, the market is segmented into antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy. The antiviral drugs segment dominated the market in 2019, accounting for more than half of the market. However, the immunosuppressant segment is expected to manifest the highest CAGR of 7.3% during the forecast period.

On the basis of disease type, the market is classified into hepatitis, autoimmune diseases, non-alcoholic fatty liver disease, cancer, genetic disorders, and others. The cancer segment is projected to portray the highest CAGR of 7.6% during the forecast period. However, the hepatitis segment held the largest share in 2019, accounting for more than four-fifths of the market.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/7546

North America liver disease treatment market is analyzed across the U.S., Canada, and Mexico. The market across Mexico is expected to manifest the highest CAGR of 6.8% during the forecast period. However, the market across the U.S. held the lion’s share in 2019, contributing to more than four-fifths of the market.

North America liver disease treatment market report includes an in-depth analysis of the major market players such as Astellas Pharma Inc., Merck & Co., Inc. (Merck Sharp & Dohme Corp.), Mylan, AbbVie Inc., Dynavax Technologies, Eli Lilly and Company, Gilead Sciences, Inc., Pfizer Inc., Emergent BioSolutions (Cangene bioPharma), and Bristol Myers Squibb.

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Avenue Library Subscription | Request for 14 days free trial of before buying: https://www.alliedmarketresearch.com/avenue/trial/starter

Get more information: https://www.alliedmarketresearch.com/library-access

Similar Reports:

Liver Disease Treatment Market - Global Opportunity Analysis and Industry Forecast, 2020–2027

Antiviral Drugs Market - Global Opportunity Analysis and Industry Forecast, 2019-2027

Vaccines Market - Global Opportunity Analysis and Industry Forecast, 2019-2027

Immunosuppressants Market - Global Opportunity Analysis and Industry Forecast, 2019–2027

Immunoglobulin Market - Global Opportunity Analysis and Industry Forecast, 2019–2027

Steroid-Corticosteroids Market - Global Opportunity Analysis and Industry Forecast, 2019–2027

Chemotherapy-induced Nausea and Vomiting (CINV) Market - Global Opportunity Analysis and Industry Forecast, 2019–2027

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

 

Contact Data